Free Stock Picks

Preliminary results from the four-year study of 1,820 people were announced Tuesday by Boston Scientific Corp., which makes the $30,000 devices known as cardiac resynchronization therapy defibrillators, or CRT-Ds, and sponsored the $38 million study. The results could lead to broadened Food and Drug Administration approval for the devices and could expand the $6.2 billion market for implanted defibrillators, which have fallen well below the optimistic projections that fueled Boston Scientific’s $28.4 billion purchase of Guidant Corp. Stock Picks report Boston Scientific.

Popularity: 26% [?]